885020-48-4

Upstream product

• 179174-80-2 (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 888010-86-4 (2Z)-4-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,4-difluorophenyl)-2-[4-(methylsulfonyl)phenyl]but-2-en-1-yl (2R)-2-propyloctanoate 
• 885020-49-5 1-tert-butyl 4-{(2Z)-4-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,4-difluorophenyl)-2-[4-(methylsulfonyl)phenyl]but-2-en-1-yl} N-(tert-butoxycarbonyl)aspartate 
• 885020-51-9 (2Z)-4-{[tert-butyl(dimethyl)silyl]oxy}-3-(3,4-difluorophenyl)-2-[4(methylsulfonyl)phenyl]but-2-en-1-yl N-2,N-6-bis(tert-butoxycarbonyl)lysinate 

Relevant academic research and scientific papers

PRODRUGS OF (2R)-2-PROPYLOCTANOIC ACID FOR TREATMENT OF STROKE

Disclosed are prodrugs of (2R)-2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating patients who have had

WATER SOLUBLE PRODRUGS OF COX-2 INHIBITORS

Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them.